Group 1: Company Performance and Product Development - The company increased R&D investment in 2024, upgrading products like oil-free screw compressors and screw vacuum pumps, maintaining steady sales growth in these categories [2] - The centrifugal compressor models completed phase application tests in 2024, with expectations for increased shipments in 2025 [2] - The company has successfully launched its first dry vacuum pump products for the semiconductor industry, with performance improvements expected in the second half of 2025 [2] Group 2: Domestic Market and Localization - The company has achieved significant progress in domestic substitution, with products being adopted in key industries such as medical, electronics, and semiconductors [2] - Major clients in the electronics sector, including Dabo Medical and Farah Electronics, have recognized the company's products, leading to repeat purchases [2] - The company has established a strong reputation in Taiwan's PCB industry, further enhancing its domestic substitution efforts [2] Group 3: International Expansion and Revenue Growth - The company exports primarily to Southeast Asian countries, with overseas revenue increasing by 18.22% year-on-year in 2024 [3] - Plans for 2025 include expanding sales channels in Southeast Asia, leveraging the Belt and Road Initiative to enhance international sales networks [3] Group 4: Future Outlook and Strategic Initiatives - The management remains optimistic about 2025, focusing on high-end product development and expanding product lines [3] - A new factory is expected to be completed in 2026, which will support the company's growth and operational strategies [3] - The company aims to adapt its business strategies based on market conditions and engage in emerging industries to enhance shareholder value [3]

Financial Performance - In the first half of 2025, the company's revenue reached 296 million CNY, representing a year-on-year increase of 27.93% [2] - The net profit attributable to shareholders was a loss of 14.31 million CNY, a decline of 153.36% year-on-year [2] - The non-recurring net profit was a loss of 16.13 million CNY, down 67.79% compared to the previous year [2] - The decline in profit is attributed to increased depreciation from fixed assets that began to be recognized in 2024 [2][3] Revenue Composition - Revenue from colored photoelectric base films accounted for 45.46% of total revenue [3] - Revenue from transparent films made up 42.62% [3] - Revenue from other functional films was 10.84%, with a decrease attributed to strategic shifts in the business focus towards window films [3] Project Updates - The carbon fiber project, initiated in Q3 2024, is currently in the critical phase of construction and equipment installation, progressing smoothly [4] Carbon Fiber Process - The carbon fiber production process involves several steps: spinning raw materials into fibers, pre-oxidation, carbonization, surface treatment, and final processing into various products [5] Application Areas - High-performance carbon fibers are increasingly used in civil aviation, 3C digital products, low-altitude aircraft, and racing, expanding the market for carbon fiber products [6] Competitive Advantages - The company focuses on technological research and development, holding key manufacturing technologies and fostering innovation through collaborations with universities [8] - It aims to enhance its product range and maintain a strong quality control system to support differentiated and functional polyester film production [8]

Group 1: Company Overview and Performance - The company has launched high-weight series products, such as "Zhenjin Zhenzuan" and "Fanghua," which have increased the average transaction value [2] - The company aims to enhance brand product strength and maintain a leading position in the industry by focusing on non-heritage flower silk and ancient craftsmanship [2] Group 2: Product Development Highlights - The company has expanded its product advantages by focusing on core customer preferences, introducing unique products like "Flower Silk • Xianyue" and "Flower Silk • Haitang" [3] - The company has added four new IP licensed products, making it the jewelry brand with the most IP images in the industry [3] Group 3: Brand Promotion Strategies - The brand promotion strategy centers around "Imagining the East • Reviving Intangible Heritage," with comprehensive marketing efforts led by brand ambassador Song Yi [4] - The company has hosted multiple themed events in key stores, resulting in significant sales growth and brand exposure [4] Group 4: Online Business Performance - The online sales subsidiary reported a net profit increase of 70.64% year-on-year, despite no growth in sales [5] - The company plans to enhance integrated operations between online and offline channels to improve overall efficiency [6] Group 5: Store Expansion and International Strategy - As of the end of August 2025, the total number of stores reached 1,540, with a net increase of 72 stores since the beginning of the year [6] - The company has successfully opened stores in Malaysia, Thailand, and Cambodia, exceeding expectations in international expansion [6]

Group 1: Sales and Production Insights - The company's steel sales volume in the first half of the year was 11.1 million tons, a year-on-year decrease of 12.6% [2] - The steel sales volume, excluding direct sales of steel billets, saw a decrease of approximately 10% [2] - The company plans to adjust production rhythm based on downstream order demand and profitability, expecting annual production and sales to match [2] Group 2: Industry Trends and Policies - The steel industry is experiencing a supply-side contraction due to strict policies on crude steel capacity and self-discipline among steel enterprises [2] - Approximately 80% of the industry capacity is expected to complete ultra-low emission transformations by the end of the year [2] - The new 2025 version of the steel industry normative conditions aims to optimize supply and eliminate backward production capacity [3] Group 3: Financial Performance and Cost Management - The company's second-quarter performance improved significantly due to a notable decline in raw material prices compared to steel prices, leading to better profitability [4] - Cost management efforts have led to improved efficiency across various cost indicators, including process, procurement, and energy costs [4] - The company is focusing on high-end steel products, maintaining a stable market share and profitability in niche markets [4] Group 4: Demand and Market Conditions - The third quarter is traditionally a slow season, with a decrease in demand for thin plate products, although some segments like automotive steel show improvement [5] - The company anticipates that industry profitability may narrow in the third quarter due to rising raw material prices, particularly coking coal [5] Group 5: Project Developments and Future Outlook - The non-oriented silicon steel project is progressing well, with the first production line expected to meet demand from key clients in the automotive sector [6] - The VAMA joint venture is operating at near full capacity, with total sales around 1.6 million tons [7] - Future developments for VAMA include the introduction of advanced steel grades and the construction of a third phase project, which is currently in feasibility studies [8][9]

Group 1: Financial Performance - The company's performance in the first half of the year, especially in Q2, showed significant improvement year-on-year and quarter-on-quarter, exceeding market expectations due to three main factors: a notable decline in raw material prices, elimination of previous short-term disruptions, and stable competition in the high-end steel market [2][4]. - In H1 2025, the company achieved a steel sales volume of 11.1 million tons, a decrease of 12.6% year-on-year, with an adjusted decline of about 10% when excluding direct sales of steel billets [8]. Group 2: Pricing and Inventory Management - The pricing for specialty steel products is negotiated individually, typically 1-2 months in advance, based on current raw material costs and customer requirements, ensuring a relatively stable profit margin compared to ordinary steel [3]. - The company maintains a lean inventory strategy, with iron ore inventory cycles of approximately 22-25 days and coal/coke inventory cycles of 10-15 days, using a first-in-first-out method for accounting [3]. Group 3: Market Outlook and Demand - The third quarter is traditionally a slow season, particularly for thin plate products, with a slight decline in demand from sectors like home appliances and engineering machinery, although there was some improvement in automotive steel orders [4]. - The company anticipates that industry profitability may narrow in Q3 due to rising raw material prices, particularly coking coal, which has increased significantly more than steel prices [4]. Group 4: Export Strategy - The company views "buy order exports" as detrimental, leading to lower overseas prices and triggering anti-dumping measures, and plans to enhance its overseas presence, particularly in the Middle East and Europe [5]. Group 5: Compliance and Industry Standards - The company has applied for "leading standard enterprise" status under the 2025 Steel Industry Norms, which aims to promote high-quality development and optimize supply in the steel industry [6][7]. Group 6: Capital Expenditure and Dividends - The company plans to invest in projects focused on product structure upgrades and ultra-low emissions, with a capital expenditure of approximately 1 billion yuan in 2025, where 40%-50% will be allocated to ultra-low emissions projects [11]. - The cash dividend ratio has steadily increased, reaching 34% of net profit for 2024, with projections for a combined ratio of 44%-54% for 2024 and 2025 due to ongoing share buyback plans [11].

Financial Performance - The company achieved revenue of 843 million CNY in the first half of 2025, a year-on-year increase of 2.40% [3] - Net profit attributable to shareholders reached 61.83 million CNY, up 12.82% year-on-year [3] - Medical services segment revenue was 653 million CNY, growing 2.28% year-on-year [3] - Medical device segment revenue was 190 million CNY, with a year-on-year increase of 2.80% [3] Oncology Services - Revenue from oncology services reached 215 million CNY, a significant increase of 25.14% [3] - The number of level IV surgeries increased by 6.62% [3] - The outpatient volume at Friendship Hospital reached 24,200 visits, up 21.59% year-on-year [3] - The proportion of level IV surgeries at Friendship Hospital increased by 8 percentage points [3] Medical Device Market - The company’s infusion pump market share exceeded 10%, ranking third in the domestic market [16] - The mammography device market share is approximately 10%, also ranking third [17] - Overseas revenue for medical devices grew by 35% year-on-year [18] AI Integration - AI applications have improved clinical capabilities, reducing complication rates by 10% and average hospital stays by 1-2 days [15] - The efficiency of image diagnosis increased by 66%, and patient follow-up efficiency improved by 300% [15] - Patient Net Promoter Score (NPS) reached 92.5%, surpassing the industry average of 90% [15] Hospital Operations - Sichuan Friendship Hospital generated revenue of 291 million CNY, maintaining stability amid competition [6] - Suzhou Guangci Hospital achieved revenue of 269 million CNY, with a year-on-year growth of 1.69% [7] - The company’s managed hospitals, including Yuncheng Hospital, have seen significant operational improvements, with surgical volumes increasing by 18% [12] Strategic Developments - The acquisition of Changsha Kexin Oncology Hospital enhances the company’s oncology ecosystem and regional presence [10] - The company is focusing on differentiated services and expanding its service ecosystem through partnerships and AI integration [9]

Industry Overview - The global renewable energy sector continues to grow rapidly, driven by low-carbon goals, policy support, improved economics, and increasing electricity demand. [2] - In the first half of 2025, global photovoltaic installations reached 310 GWac, a 60% year-on-year increase, with China's grid-connected capacity growing by 107% to 212 GW. [2][3] - Global lithium battery storage capacity reached 109 GWh, up 68% year-on-year, with domestic installations increasing by 62% to 50 GWh. [3] - The domestic wind power market saw a significant increase, with installations rising from 26 GW to 51 GW, nearly doubling year-on-year. [3] Company Performance - In the first half of 2025, the company achieved revenue of 43.5 billion yuan, a 40% increase year-on-year, and a net profit of 7.7 billion yuan, up 56%. [4] - The gross margin improved from 32.4% to 34.4%, and earnings per share rose from 2.4 yuan to 3.7 yuan. [4] - The company’s core competitiveness and brand influence have strengthened, contributing to its market leadership. [4] Business Segments Inverter Business - Revenue from the photovoltaic inverter segment reached 13.4 billion yuan, an 11% increase year-on-year, supported by a strong market position and brand premium. [7] - The company launched two new inverter products, including the world's first 400 kW+ string inverter. [7] Energy Storage Business - The energy storage segment generated 17.8 billion yuan in revenue, a 128% increase year-on-year, driven by strong global demand and a solid brand reputation. [8] - The company introduced the PowerTitan 3.0 AC storage platform, enhancing its product offerings. [8] New Energy Investment - Revenue from new energy investment development was 8.4 billion yuan, slightly down year-on-year, primarily due to policy impacts on household photovoltaics. [9] Financial Management - The company reported a net cash flow from operating activities of 3.4 billion yuan, a significant improvement from -2.6 billion yuan in the previous year. [7] - Accounts receivable decreased by 140 million yuan to 27.5 billion yuan, while inventory increased by 700 million yuan to 29.7 billion yuan. [10] - R&D expenses rose by 37% to 2.04 billion yuan, reflecting the company's commitment to innovation and product development. [12] Shareholder Returns - The company plans to increase its dividend payout ratio to 25%, distributing approximately 1.95 billion yuan in cash dividends to shareholders. [9] Future Outlook - The company anticipates a compound annual growth rate of 20-30% in the global energy storage market over the next few years. [16] - The European market is expected to be a key growth area, with ongoing investments in technology and product innovation. [17] - The U.S. market is projected to maintain strong growth due to ongoing subsidies and increasing demand for renewable energy solutions. [18]

Group 1: Business Performance and Strategy - The company aims to enhance the operational quality of existing stores, with a reported revenue growth of over 20% year-on-year in the first half of 2025 [2] - The company plans to launch new products and strengthen online and offline channel collaboration to expand its hearing business [2] - The overseas business achieved nearly 100 million in revenue, with a year-on-year growth exceeding 200% [4] Group 2: Investments and Acquisitions - The company invested in NeuLink Medical in May 2024 to explore advanced hearing rehabilitation solutions through brain-machine interface technology [3] - In January 2025, the company completed a controlling acquisition of Shanghai Huazhou, enhancing its product line and overseas market channels [4] - The company also acquired a controlling stake in Ximan Na in June 2025, facilitating entry into the Hong Kong market [4] Group 3: Online Sales and Market Trends - The company has developed a comprehensive product matrix covering five major areas, maintaining strong sales performance on mainstream e-commerce platforms [6] - Interest e-commerce platforms have gained popularity, prompting the company to invest in innovative content to enhance brand visibility and product sales [6] Group 4: AI and Technology Development - The company is advancing AI applications across various medical devices, focusing on interconnectivity and data exchange [7] - The upcoming Kefu Health APP will integrate data from multiple devices to provide personalized health management solutions [7] Group 5: Core Product Strategy - The company focuses on core product categories that contribute significantly to revenue and have growth potential, including respiratory machines and hearing aids [8] - Continuous improvement in product quality and market share is a priority, with plans for iterative upgrades and cost reductions [8] Group 6: Respiratory Device Performance - The company's self-developed respiratory machines have received high consumer recognition, with sales rapidly increasing since late June 2025 [9]

中信泰富特钢集团股份有限公司 投资者关系活动记录表 编号：2025-003 | 投资者关 | □特定对象调研 分析师会议 | | --- | --- | | 系活动类 | □媒体采访 业绩说明会 | | | □新闻发布会 □路演活动 | | 别 | | | | □现场参观 √其他 电话会议 | | 参与单位 | 中信证券 唐川林、长江证券 赵超、长江证券 吕士诚、广发证券 陈 | | 名称及人 | 琪玮、国信证券 焦方冉、光大证券 戴默、东方证券 黄雨韵、浙 | | 员姓名 | 商证券 沈皓俊、国泰海通证券 王宏玉、中金证券 张树玮、申万 | | 证券 | 王明路、景顺长城 尤木等 | | 时间 2025 | 年 8 月 25 日 15:30-16:30 | | 地点 | 线上电话会议 | | 上市公司 | 董事、总裁 罗元东先生 | | 接待人员 | 董事会秘书 王海勇先生 | | 姓名 | 副总会计师 吴 斌先生 | | | 证券事务代表 杜 鹤先生 | | 投资者关 | 第一部分：管理层介绍公司 2025 年半年度经营情况 | | 系活动主 | 由公司董事、总裁罗元东先生介绍 2025 年上半年业绩 ...

Group 1: Financial Performance - The company achieved a revenue of 1.708 billion CNY, a year-on-year increase of 20.53% [3] - Net profit attributable to the parent company reached 257 million CNY, reflecting a growth of 57.59% [3] - The net profit excluding non-recurring gains and losses was 188 million CNY, up 34.28% year-on-year [3] Group 2: Business Segments - The animal health business focused on major clients, significantly boosting revenue from biological products, which became a key growth driver [3] - The pet health segment generated 415 million CNY, a year-on-year increase of 17.94% [5] - The poultry segment saw a revenue of 611 million CNY, growing by 24.71% [9] Group 3: Research and Development - R&D investment reached 114 million CNY, accounting for 6.67% of revenue [3] - The company obtained 4 new veterinary drug registration certificates and 6 clinical trial approvals, including the world's first mRNA vaccine for food animals [3][8] - The R&D achievements contributed to the company's position in the global animal health industry [8] Group 4: Operational Efficiency - The company improved its gross margin by 2.36 percentage points, driven by revenue expansion and product structure optimization [4] - Lean transformation initiatives led to a reduction in sales and management expense ratio by 0.84 percentage points [4] - The raw material drug segment improved its gross margin by 14 percentage points, significantly reducing losses [6] Group 5: Strategic Initiatives - The company is enhancing its supply chain and product matrix in the pet health sector, with plans to launch new products such as cat interferon and probiotics [5] - Strategic partnerships with leading breeding groups are being developed to deepen service and cooperation [4] - The company is focusing on international market expansion and optimizing product structure to increase profitability [6]